These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 35123927)

  • 1. SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
    Romancik JT; Gerber DG; Zhuang T; Cohen JB
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):557-565. PubMed ID: 35123927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions.
    Bond DA; Martin P; Maddocks KJ
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33799484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
    Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
    Munoz JL; Wang Y; Jain P; Wang M
    Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
    Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
    Nayak RK; Gerber D; Zhang C; Cohen JB
    Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):861-865. PubMed ID: 37661513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
    Owen C; Berinstein NL; Christofides A; Sehn LH
    Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
    Tbakhi B; Reagan PM
    Ther Adv Hematol; 2022; 13():20406207221080738. PubMed ID: 35237395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapies for relapsed/refractory mantle cell lymphoma.
    Arora PC; Portell CA
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
    Eyre TA; Shah NN; Dreyling M; Jurczak W; Wang Y; Cheah CY; Song Y; Gandhi M; Chay C; Sharman J; Andorsky DJ; Messersmith HM; Ruppert AS; Muthig VA; Ito R; Wang ML
    Future Oncol; 2022 Nov; 18(36):3961-3969. PubMed ID: 36377973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects.
    Raghani NR; Shah DD; Shah TS; Chorawala MR; Patel RB
    Crit Rev Oncol Hematol; 2023 Oct; 190():104085. PubMed ID: 37536448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
    Burkart M; Karmali R
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing of Novel Therapies for Mantle Cell Lymphoma.
    Romancik JT; Cohen JB
    Curr Treat Options Oncol; 2021 Nov; 22(12):118. PubMed ID: 34812968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.
    Morabito F; Recchia AG; Vigna E; Botta C; Skafi M; Abu-Rayyan M; Atrash M; Galimberti S; Morabito L; Al-Janazreh H; Martino M; Cutrona G; Gentile M
    Expert Opin Pharmacother; 2020 Jan; 21(1):29-38. PubMed ID: 31738609
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide for the treatment of mantle cell lymphoma.
    Morabito F; Skafi M; Recchia AG; Kashkeesh A; Hindiyeh M; Sabatleen A; Morabito L; Alijanazreh H; Hamamreh Y; Gentile M
    Expert Opin Pharmacother; 2019 Apr; 20(5):487-494. PubMed ID: 30608891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma.
    Marchetti M; Visco C
    Leuk Lymphoma; 2023; 64(8):1442-1450. PubMed ID: 37229538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.